Myeloid-derived suppressor cells in secondary sepsis: Is there an association with lethal outcome?

Udovičić, Ivo; Šurbatović, Maja; Rondović, Goran; Stanojević, Ivan; Zeba, Snježana; Djordjević, Dragan; Popadić, Ana; Milosavljevic, Snezana; Stanković, Nikola; Abazović, Džihan; Vojvodić, Danilo

doi:10.2298/vsp180706133u

Cited by 3 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Demografic and clinical data of forty patients are shown on Table 1. Detailed description is presented in our previous study (5). Two patients with sterile blood cultures were excluded from further analysis.…”

Section: Resultsmentioning

confidence: 99%

“…Approval in concordance with Declaration of Helsinki was obtained from local ethics committee and informed consent from a patient or first-degree relative. Detailed description of study population is reported elsewhere (5). Blood samples for MDSCs analysis were collected on admission -Day 1 and on Day 5.…”

Section: Patientsmentioning

confidence: 99%

“…Both main subsets of MDSCs were detected, the granulocytic (G-MDSCs) and the monocytic subset (M-MDSCs). MDSCs analysis is described elsewhere (5).…”

Section: Sampling and Analysismentioning

confidence: 99%

See 2 more Smart Citations

Do nature of bacteremia and origin of secondary sepsis in critically ill patients determine subset of myeloid-derived suppressor cells expansion?

Udovičić

Šurbatović

Rondović

et al. 2020

VSP

Self Cite

View full text Add to dashboard Cite

Background / Aim. Gram-positive and Gram-negative bacteria may induce different inflammatory patterns. The aim of our study were to examine the association of the myeloid-derived suppressor cells (MDSCs) with the type of infecting microorganism (Gram positive, Gram negative, polymicrobial) and underlying cause of secondary sepsis (peritonitis, pancreatitis, trauma). Methods. Total of 40 critically ill patients with secondary sepsis were enrolled in prospective study. Two, without documented positive blood culture were excluded. We detected and enumerated both main subsets of MDSCs: Granulocytic (G)-MDSCs and Monocytic (M)-MDSCs on Day 1 and Day 5. Blood was simultaneously drawn for a blood culture. Results. We found that both main MDSC subpopulations accumulate significantly in Gram-positive sepsis. Univariate logistic regression analyses of investigated variables regarding Gram-positive sepsis on Day 5 revealed that G-MDSCs absolute number along with both M-MDSCs frequency and absolute number had statistically significant power for predicting Gram-positive sepsis. Stepwise multivariate logistic regression analyses of the variables on Day 5 determined that M-MDSCs absolute number was independent predictor of Gram-positive sepsis (OR 1.012; p<0.05). Clinical accuracy of Neutrophil/G-MDSCs (Ne/G-MDSCs) and Monocyte/M-MDSCs (Mo/M-MDSCs) ratios in predicting nature of bacteremia and outcome was investigated. Discriminative power of both Ne/G-MDSCs and Mo/M-MDSCs ratios in predicting Gram-positive blood culture was statistically significant both on Day 1 and Day 5 (AUCs 0.684, 0.692, 0.707 and 0.793 respectively). Ne/G-MDSCs both on Day 1 and Day 5 were statistically significant predictors of lethal outcome (AUCs of 0.694 and 0.678 respectively). The patients with different underlying causes of sepsis (peritonitis, pancreatitis, trauma) were perceived as separated groups and the frequencies and absolute numbers of their G-MDSCs and M-MDSCs were compared. There were no statistically significant diffrences between these three groups neither on Day 1 nor on Day 5. Conclusions. Gram-positive infectious agents were powerful inducers of MDSCs generation in sepsis. Also, underlying causes of secondary sepsis might not seem to influence the MDSCs accumulation.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Do nature of bacteremia and origin of secondary sepsis in critically ill patients determine subset of myeloid-derived suppressor cells expansion?

Udovičić

Šurbatović

Rondović

et al. 2020

VSP

Self Cite

View full text Add to dashboard Cite

show abstract

“…Bacterial sepsis and severe COVID-19 have been investigated from a genetic point of view, focusing on potential differences in gene signature. Myeloid-derived suppressor cells (MDSCs) have been extensively investigated in bacterial sepsis by many investigators, including our group [ 26 , 27 ]. An in-depth analysis of these fascinating cells was performed by Reyes et al using single-cell RNA-sequencing to profile the blood of patients with bacterial sepsis [ 28 ].…”

Section: Aspects Of Host Response—how Specific Are They For Covid-19?mentioning

confidence: 99%

From Cytokine Storm to Cytokine Breeze: Did Lessons Learned from Immunopathogenesis Improve Immunomodulatory Treatment of Moderate-to-Severe COVID-19?

et al. 2022

View full text Add to dashboard Cite

Complex immune response to infection has been highlighted, more than ever, during the COVID-19 pandemic. This review explores the immunomodulatory treatment of moderate-to-severe forms of this viral sepsis in the context of specific immunopathogenesis. Our objective is to analyze in detail the existing strategies for the use of immunomodulators in COVID-19. Immunomodulating therapy is very challenging; there are still underpowered or, in other ways, insufficient studies with inconclusive or conflicting results regarding a rationale for adding a second immunomodulatory drug to dexamethasone. Bearing in mind that a “cytokine storm” is not present in the majority of COVID-19 patients, it is to be expected that the path to the adequate choice of a second immunomodulatory drug is paved with uncertainty. Anakinra, a recombinant human IL-1 receptor antagonist, is a good choice in this setting. Yet, the latest update of the COVID-19 Treatment Guidelines Panel (31 May 2022) claims that there is insufficient evidence to recommend either for or against the use of anakinra for the treatment of COVID-19. EMA’s human medicines committee recommended extending the indication of anakinra to include treatment of COVID-19 in adult patients only recently (17 December 2021). It is obvious that this is still a work in progress, with few ongoing clinical trials. With over 6 million deaths from COVID-19, this is the right time to speed up this process. Our conclusion is that, during the course of COVID-19, the immune response is changing from the early phase to the late phase in individual patients, so immunomodulating therapy should be guided by individual responses at different time points.

show abstract

“…Our group investigated myeloid-derived suppressor cells (MDSCs) in critically ill patients with sepsis [204,302]. MDSC-like neutrophils isolated from COVID-19 patients have the capability to inhibit T cell proliferation and IFN-γ release [303,304].…”

Section: Immunopathogenesis Of Coronavirus Disease 2019-covid-19mentioning

confidence: 99%

Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19

Udovičić

Stanojević

Djordjević

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

Immune cells and mediators play a crucial role in the critical care setting but are understudied. This review explores the concept of sepsis and/or injury-induced immunosuppression and immuno-inflammatory response in COVID-19 and reiterates the need for more accurate functional immunomonitoring of monocyte and neutrophil function in these critically ill patients. in addition, the feasibility of circulating and cell-surface immune biomarkers as predictors of infection and/or outcome in critically ill patients is explored. It is clear that, for critically ill, one size does not fit all and that immune phenotyping of critically ill patients may allow the development of a more personalized approach with tailored immunotherapy for the specific patient. In addition, at this point in time, caution is advised regarding the quality of evidence of some COVID-19 studies in the literature.

show abstract

Myeloid-derived suppressor cells in secondary sepsis: Is there an association with lethal outcome?

Cited by 3 publications

References 35 publications

Do nature of bacteremia and origin of secondary sepsis in critically ill patients determine subset of myeloid-derived suppressor cells expansion?

Do nature of bacteremia and origin of secondary sepsis in critically ill patients determine subset of myeloid-derived suppressor cells expansion?

From Cytokine Storm to Cytokine Breeze: Did Lessons Learned from Immunopathogenesis Improve Immunomodulatory Treatment of Moderate-to-Severe COVID-19?

Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19

Contact Info

Product

Resources

About